Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial.
Anna Maria Di Giacomo(University of Siena), Michele Maio(University of Siena), Pier Francesco Ferrucci(MultiMedica), Massimo Guidoboni(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ruggero Ridolfi, Antonella Marasco, Diego Annesi(University of Siena), Giorgio Parmiani(Fondazione IRCCS Istituto Nazionale dei Tumori), Paola Queirolo, Ester Simeone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Diana Giannarelli(Agostino Gemelli University Polyclinic), Mario Santinami(Fondazione IRCCS Istituto Nazionale dei Tumori), Ester Fonsatti(Istituto di Chimica Biomolecolare), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Lorenzo Pilla(Université Paris Cité), Alessandro Testori(European Organisation for Research and Treatment of Cancer)
Cited by 7
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k